Allergic Rhinitis and Asthma Symptoms in a Real-Life Study of MP-AzeFlu to Treat Multimorbid Allergic Rhinitis and Asthma

David Price* (Corresponding Author), Ludger Klimek, Gabriella Galffy, Melanie Emmeluth, Arkady Koltun, Ferdinand Kopietz, Duc Tung Nguyen, Ranny Van Weissenbruch, Wolfgang Pohl, Hans Christian Kuhl, Glenis Scadding, Joaquim Mullol

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)
3 Downloads (Pure)



Asthma affects up to nearly 40% of patients with allergic rhinitis (AR). Poor control of AR symptoms is associated with poor asthma control. The goal of this study was to evaluate the effect of AR treatment with MP-AzeFlu on symptoms of AR as well as symptoms of asthma.


This prospective study used a visual analog scale (VAS) to assess symptoms of AR and asthma before and after treatment with MP-AzeFlu (Dymista®; azelastine hydrochloride plus fluticasone propionate; 1 spray in each nostril twice daily for 2 weeks). Participants suffered from moderate-to-severe AR according to Allergic Rhinitis and its Impact on Asthma criteria, with acute AR symptoms (AR-VAS scores ≥ 50 mm) on inclusion day. In addition to symptom assessment, patients recorded the impact of AR symptoms on quality-of-life measures before, during, and at the conclusion of the treatment period (approximately 14 days). Patients self-reported change in frequency of their usage of asthma reliever medication on the last day of treatment.


Of 1103 study participants, 267 (24.2%) had comorbid asthma. These participants reported using a mean of 5.1 puffs of asthma reliever medication in the week before treatment with MP-AzeFlu. A total of 81.8% of patients with comorbid asthma responded to AR therapy (AR-VAS < 50 mm on at least 1 study day). Among patients with AR and comorbid asthma, MP-AzeFlu was associated with improved VAS scores across all study parameters, including AR symptom severity, asthma symptom severity, sleep quality, daily work or school activities, daily social activities, and daily outdoor activities. Asthma symptom severity decreased from a mean of 48.9 mm to 24.1 mm on the VAS. Self-reported frequency of asthma reliever medication use was reduced for 57.6% of participants (n = 139/241).


MP-AzeFlu used to relieve AR symptoms was associated with reduced asthma symptom VAS scores and frequency of asthma reliever medication usage. Changes in overall symptoms of AR and asthma were correlated.

Original languageEnglish
Article number15
Number of pages10
JournalClinical and Molecular Allergy
Publication statusPublished - 6 Aug 2020

Bibliographical note

We would like to thank the subjects who participated in the trial.

This study was supported by MEDA Pharma GmbH & Co. KG (A Mylan Company), Bad Homburg, Germany. Technical, editorial, and medical writing assistance was provided under the direction of the authors by Strategix, an affiliate of The Lynx Group, LLC. Funding for this support was provided by Mylan Inc.


  • allergic rhinitis
  • asthma
  • comorbidity
  • daily activity
  • MP-AzeFlu
  • sleep quality
  • visual analog scale
  • Daily activity
  • Comorbidity
  • Asthma
  • Visual analog scale
  • Sleep quality
  • Allergic rhinitis


Dive into the research topics of 'Allergic Rhinitis and Asthma Symptoms in a Real-Life Study of MP-AzeFlu to Treat Multimorbid Allergic Rhinitis and Asthma'. Together they form a unique fingerprint.

Cite this